These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 19808642

  • 1. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
    Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R.
    Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
    [Abstract] [Full Text] [Related]

  • 2. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 3. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, Karnezis T, Stacker SA, Achen MG.
    J Biol Chem; 2016 Dec 30; 291(53):27265-27278. PubMed ID: 27852824
    [Abstract] [Full Text] [Related]

  • 4. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.
    Prostate; 2013 May 30; 73(6):563-72. PubMed ID: 23038639
    [Abstract] [Full Text] [Related]

  • 5. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
    Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY.
    Mol Cancer; 2011 Apr 11; 10():36. PubMed ID: 21481239
    [Abstract] [Full Text] [Related]

  • 6. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
    Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, Albuquerque R, Ambati J, Wilting J.
    Clin Cancer Res; 2010 Mar 01; 16(5):1431-41. PubMed ID: 20179233
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S, Helske S, Lappalainen J, Kupari M, Kovanen PT.
    Atherosclerosis; 2012 Apr 15; 221(2):366-74. PubMed ID: 22281299
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
    Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K.
    J Biol Chem; 2006 Apr 28; 281(17):12187-95. PubMed ID: 16505489
    [Abstract] [Full Text] [Related]

  • 14. Hyaluronan-induced VEGF-C promotes fibrosis-induced lymphangiogenesis via Toll-like receptor 4-dependent signal pathway.
    Jung YJ, Lee AS, Nguyen-Thanh T, Kang KP, Lee S, Jang KY, Kim MK, Kim SH, Park SK, Kim W.
    Biochem Biophys Res Commun; 2015 Oct 23; 466(3):339-45. PubMed ID: 26362177
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lymphangiogenesis-independent resolution of experimental edema.
    Ongstad EL, Bouta EM, Roberts JE, Uzarski JS, Gibbs SE, Sabel MS, Cimmino VM, Roberts MA, Goldman J.
    Am J Physiol Heart Circ Physiol; 2010 Jul 23; 299(1):H46-54. PubMed ID: 20207821
    [Abstract] [Full Text] [Related]

  • 17. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
    Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K.
    Proc Natl Acad Sci U S A; 2010 Feb 09; 107(6):2425-30. PubMed ID: 20145116
    [Abstract] [Full Text] [Related]

  • 18. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
    Wuest TR, Carr DJ.
    J Exp Med; 2010 Jan 18; 207(1):101-15. PubMed ID: 20026662
    [Abstract] [Full Text] [Related]

  • 19. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
    Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, Kiss JZ, Dietrich PY, De Tribolet N, Pizzolato GP, Pepper MS.
    J Pathol; 2006 May 18; 209(1):34-43. PubMed ID: 16523449
    [Abstract] [Full Text] [Related]

  • 20. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
    Hos D, Regenfuss B, Bock F, Onderka J, Cursiefen C.
    Invest Ophthalmol Vis Sci; 2011 Jul 29; 52(8):5778-85. PubMed ID: 21666240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.